Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.43 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 8/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 2/20 | 0.31 |
| ▸ | CCR9 | P51686 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15489482 | 0.87 | MCL1 (0.33) | MCL1FDPSALDH1A1 | |
| SCHEMBL19615178 | 0.73 | MCL1 (0.37) | MCL1FDPSDAOCCR2 | |
| SCHEMBL22687067 | 0.71 | MCL1 (0.57) | MCL1FDPSDAOCCR2ALDH1A1 | |
| SCHEMBL30832178 | 0.70 | MCL1 (0.52) | MCL1FDPSDAOCCR2ALDH1A1 | |
| SCHEMBL30832172 | 0.70 | MCL1 (0.40) | MCL1FDPSDAOCCR2ALDH1A1 | |
| SCHEMBL6330126 | 0.64 | MCL1 (0.46) | MCL1FDPSDAOCCR2ALDH1A1 | |
| SCHEMBL28844727 | 0.64 | CCR2 (0.51) | MCL1FDPSDAOCCR2ALDH1A1 | |
| SCHEMBL4501824 | 0.61 | — | — | |
| SCHEMBL3229944 | 0.61 | MCL1 (0.57) | MCL1FDPSDAOCCR2ALDH1A1 | |
| SCHEMBL10233030 | 0.61 | MCL1 (0.57) | MCL1FDPSDAOCCR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | MCL1 687/4885FDPS 4583/4885DAO 1674/4885 |
| US-11667645-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | MCL1 687/4885FDPS 4583/4885DAO 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.